Valuation: Solid Biosciences Inc.

Market Cap 860M 756M 710M 650M 1.21B 82.32B 1.22B 8.52B 3.3B 41.99B 3.23B 3.16B 136B P/E 2026 *
-4.62x
P/E 2027 * -4.69x
Enterprise Value 566M 498M 467M 428M 798M 54.2B 805M 5.61B 2.17B 27.65B 2.13B 2.08B 89.66B EV / Sales 2026 *
-
EV / Sales 2027 * 64.9x
Free-Float
88.22%
Yield 2026 *
-
Yield 2027 * -
1 day-10.09%
1 week-4.18%
Current month-16.28%
1 month-13.76%
3 months-3.37%
6 months+14.08%
Current year+42.20%
1 week 8
Extreme 8.001
9.03
1 month 8
Extreme 8.001
10.48
Current year 4.92
Extreme 4.92
11.45
1 year 3.79
Extreme 3.79
11.45
3 years 1.81
Extreme 1.81
15.05
5 years 1.81
Extreme 1.81
44.07
10 years 1.81
Extreme 1.81
822.6
Manager TitleAgeSince
Chief Executive Officer 55 2022-12-01
Corporate Officer/Principal - 2014-08-31
Director of Finance/CFO 48 2023-01-08
Director TitleAgeSince
Director/Board Member 52 2013-02-28
Director/Board Member 60 2015-10-31
Director/Board Member 46 2015-10-31
Date Insider Type Main position Quantity % Market Cap. Importance
7/2/26 Exercice

Chairman

6,880 0.0070%
6/10/26 Free

Founder

77,500 0.0787%
4/2/26 Exercice

Chairman

6,882 0.0070%
Change 5-day change 1-year change 3-year change Capi.($)
-10.09%-4.18%+55.13%+190.58% 956M
+0.06%+7.20%+54.04%+111.13% 74.27B
-2.29%-2.68%+32.41%+75.07% 61.21B
+0.28%+7.27%+31.74%+23.80% 27.55B
-2.05%-1.32%-18.40%+352.20% 26.38B
-2.39%+1.83%-0.26%-5.91% 25.34B
+0.57%+6.60%+26.25%-9.37% 20.84B
-1.47%+4.46%-8.09%+513.33% 14.94B
+1.29%-2.49%+163.31%+333.06% 15.17B
-2.44%-0.30%+43.33%+164.11% 14.41B
Average -1.85%+3.54%+37.95%+174.80% 28.11B
Weighted average by Cap. -0.99%+3.09%+35.44%+134.21%

Financials

2026 *2027 *
Net sales - 9.2M 8.08M 7.59M 6.95M 12.96M 880M 13.07M 91.15M 35.32M 449M 34.53M 33.77M 1.46B
Net income -226M -198M -186M -170M -318M -21.6B -321M -2.24B -867M -11.02B -847M -829M -35.73B -243M -213M -200M -183M -342M -23.22B -345M -2.4B -931M -11.84B -911M -891M -38.4B
Net Debt -294M -258M -242M -222M -414M -28.12B -417M -2.91B -1.13B -14.34B -1.1B -1.08B -46.52B -263M -231M -217M -199M -371M -25.22B -374M -2.61B -1.01B -12.86B -989M -967M -41.71B
Logo Solid Biosciences Inc.
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Employees
121
Date Price Change Volume
26-09-23 US$8.020 -10.09% 1,086,918
26-09-22 US$8.920 +4.45% 1,305,487
26-09-21 US$8.540 -4.15% 1,170,809
26-09-18 US$8.910 +0.45% 4,090,597
26-09-17 US$8.870 +1.72% 1,193,532
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
8.020USD
Average target price
18.62USD
Spread / Average Target
+132.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SLDB Stock